Coronavirus / COVID

Regular symptom screening revealed completely asymptomatic COVID-19 infection is highly unlikely among unvaccinated people.

As the number of COVID-19 cases continues to rise, oral treatment options for at-home use are in demand to provide early intervention and reduce the progression to severe disease, hospitalization, and death.

For people living with HIV (PLWH) an accelerated aging process may affect the severity of their disease.

After presenting at CROI 2022, Dr. Jessica Justman discusses her community-level survey findings: COVID-19 infections do not vary by age.

Investigators looked at full vaccination and booster dose observational data to offer some insights on protection and breakthrough infections.

The idea of a future with COVID-19 is settling in, and building strategies that improve quality of life as we live with this viral disease are paramount.

Data shown in the Pinetree clinical trial and being presented with 2 posters at CROI demonstrate both benefits and safety in preventing progression to more severe disease.

In a study of people living with HIV in Taiwan, COVID-19 vaccination was highly effective when implemented alongside non-pharmaceutical interventions.

A research agenda focusing on breakthrough infections, reinfections, severity, and sequelae is needed to inform clinical practice when COVID-19 emphasis shifts from eradication to living with the disease.

Convalescent plasma safely raised antibody levels in children at high risk of severe or fatal COVID-19, successfully neutralizing the virus but unlikely to provide lasting protection.

This decision was based from the analysis of the company’s phase 2 BLAZE-4 trial.

Pfizer-BioNTech previously asked for FDA approval to administer its COVID-19 vaccine in children 6 months-4 years of age, but has deferred the request after reviewing more data.

In this latest episode of Contagion Community, we interview Dr. Jacinda Abdul-Mutakabbir about vaccine equality vs vaccine equity as well as her experience on a COVID-19 vaccine drive to increase vaccinations in communities of color.

Their investigational vaccine, NVX-CoV2373, demonstrated 82% efficacy against the Delta variant in participants 12-17 years old.

A study looked at COVID-19 vaccination rates and new COVID-19 infections across US counties during the Delta surge last summer. Many of the highly infected counties were considered rural, highlighting some of the vaccination challenges surrounding these areas.

COVID-19 vaccination rates were higher in counties with more primary care physicians, suggesting doctors are in unique positions of trust with their patients and can encourage vaccination.

32% of older adults had 1 or more new, persistent clinical conditions after COVID-19 infection.

Trying to increase COVID-19 vaccination rates in these populations has been challenging. In an attempt to do so, a randomized clinical trial across 133 skilled nursing facilities (SNFs) was performed.

Intranasal COVID-19 vaccines aren’t just needle and pain-free—they may also be more effective at protecting against current and future variants.

Omicron's numerous spike protein mutations caused mass concern, but one research team hypothesizes that its mutations are largely documented and thus susceptible to COVID-19 vaccination.

A recent study in Guangdong, China, confirmed vaccine effectiveness of inactivated COVID-19 vaccines against the Delta variant of COVID-19.

Not all people unvaccinated against COVID-19 people are actively avoiding the vaccine. A new study shows that Black people were vaccinated at lower rates than White people in the US early on, even after they indicated they were willing to get the shot. The study’s authors explain the reasons behind this.

During spring 2021, when Alpha was the dominant COVID-19 variant, a midsized Midwestern university’s vaccination initiative was associated with a significant decrease in COVID-19 infections.

Low COVID-19 vaccination rates among Hispanic populations may be due to limited vaccine information available in Spanish.

The company recently submitted its data to the federal regulatory authorities for an Emergency Use Authorization of its COVID-19 vaccine, NVX-CoV2373. As it's time to think about this potential vaccine being available in the US, clinicians offer some insights and perspective on it.